TGF-β uncouples glycolysis and inflammation in macrophages and controls survival during sepsis

Thierry Gauthier,Chen Yao,Tyrone Dowdy,Wenwen Jin,Yun-Ji Lim,Liliana C Patiño,Na Liu,Shannon I Ohlemacher,Andrew Bynum,Rida Kazmi,Carole A Bewley,Mladen Mitrovic,Daniel Martin,Robert J Morell,Michael Eckhaus,Mioara Larion,Roxane Tussiwand,John J O'Shea,WanJun Chen
DOI: https://doi.org/10.1126/scisignal.ade0385
2023-08-08
Abstract:Changes in metabolism of macrophages are required to sustain macrophage activation in response to different stimuli. We showed that the cytokine TGF-β (transforming growth factor-β) regulates glycolysis in macrophages independently of inflammatory cytokine production and affects survival in mouse models of sepsis. During macrophage activation, TGF-β increased the expression and activity of the glycolytic enzyme PFKL (phosphofructokinase-1 liver type) and promoted glycolysis but suppressed the production of proinflammatory cytokines. The increase in glycolysis was mediated by an mTOR-c-MYC-dependent pathway, whereas the inhibition of cytokine production was due to activation of the transcriptional coactivator SMAD3 and suppression of the activity of the proinflammatory transcription factors AP-1, NF-κB, and STAT1. In mice with LPS-induced endotoxemia and experimentally induced sepsis, the TGF-β-induced enhancement in macrophage glycolysis led to decreased survival, which was associated with increased blood coagulation. Analysis of septic patient cohorts revealed that the expression of PFKL, TGFBRI (which encodes a TGF-β receptor), and F13A1 (which encodes a coagulation factor) in myeloid cells positively correlated with COVID-19 disease. Thus, these results suggest that TGF-β is a critical regulator of macrophage metabolism and could be a therapeutic target in patients with sepsis.
What problem does this paper attempt to address?